1169699-61-9

Upstream product

• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 79-04-9 chloroacetyl chloride 
• 1391602-69-9 N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide 
• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 39143-25-4 1-benzyl-4-amino-4-piperidinecarboxylic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1160247-03-9 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 1391602-71-3 1-methyl-4-oxa-1,9-diaza-spiro[5,5]undecan-2-one hydrochloride 

Relevant academic research and scientific papers

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

Opioid receptor agonists and application thereof

The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.

1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to 1,9-diazaspiro undecane compounds having this pharmacological activity, to processes of

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.